CSL Ltd
ASX:CSL
CSL Ltd
Net Income (Common)
CSL Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
CSL Ltd
ASX:CSL
|
Net Income (Common)
$2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Immutep Ltd
ASX:IMM
|
Net Income (Common)
-AU$40.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-12%
|
|
Mesoblast Ltd
ASX:MSB
|
Net Income (Common)
-$73.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Net Income (Common)
AU$30.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Income (Common)
AU$5.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Net Income (Common)
-AU$21.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-23%
|
See Also
What is CSL Ltd's Net Income (Common)?
Net Income (Common)
2.5B
USD
Based on the financial report for Dec 31, 2023, CSL Ltd's Net Income (Common) amounts to 2.5B USD.
What is CSL Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
7%
Over the last year, the Net Income (Common) growth was 17%. The average annual Net Income (Common) growth rates for CSL Ltd have been -2% over the past three years , 7% over the past five years , and 7% over the past ten years .